These observations lead to the question whether the observed crosstalk between DOT1L and HDAC1 in mouse T cells plays a role in the therapeutic effect of pan-HDAC inhibition in human CTCL. Here, DOT1L is linked to primary cutaneous T-cell non-Hodgkin lymphoma.